DiscGenics Appoints Former Medtronic Spine and Biologics Finance Executive as First Chief Financial Officer

Shared by 09/10/2020
Gavin Crowther

SALT LAKE CITYSept. 9, 2020 /PRNewswire/ —DiscGenics, Inc., a clinical stage biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced it has appointed former Medtronic Spine and Biologics finance executive, Jeff Poole, as its first Chief Financial Officer (CFO).